# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jack London (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET010-SYN-TD
- Date: 1915-08-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Whitcombe-Ibe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation. **S**

## Objective

Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 28 mg/dL (high); Creatinine: 1.98 mg/dL (high); Glucose: 94 mg/dL; eGFR (CKD-EPI 1910): 43 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 240 mg/g (high); Uric acid: 8.4 mg/dL (high); Calcium: 9.2 mg/dL; Phosphate: 3.8 mg/dL; Parathyroid hormone, intact: 74 pg/mL (high); Hemoglobin: 13.6 g/dL; MCV: 101 fL (high); Platelets: 182 10*3/uL; AST: 68 U/L (high); ALT: 41 U/L; GGT: 186 U/L (high); Albumin: 4.1 g/dL; Total bilirubin: 0.9 mg/dL; INR: 1; PEth (alcohol marker): 410 ng/mL (high); HbA1c: 5.4%; Total cholesterol: 214 mg/dL (high); HDL cholesterol: 58 mg/dL; LDL cholesterol (calculated): 128 mg/dL; Triglycerides: 140 mg/dL; AUDIT: 27; PHQ-9: 9; GAD-7: 7. All results are synthetic.

BP 158/98 mmHg; pulse 92 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 97% on room air; weight 84.2 kg; BMI 28.1 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultation; Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mL; Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its place; Cigarette smoking, about ten a day; not ready to stop while he stops drinking. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Stopped: Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intake **S**
- Started: Losartan 50 mg oral tablet once daily **S**
- Started: Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone check **S**
- Started: Thiamine 100 mg oral tablet once daily **S**
- Started: Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen **S**

## Plan

- Kidneys and blood pressure: creatinine with eGFR (CKD-EPI 1910), urine albumin-to-creatinine ratio and urinalysis with microscopy, electrolytes and bicarbonate, uric acid, calcium, phosphate and PTH, blood count, HbA1c and a lipid panel once; the earlier insurance creatinine obtained; ultrasound of the kidneys and liver; standardized office blood pressure at every visit and home readings. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Nephrology consultation to confirm the stage and cause of the kidney disease and advise on blood pressure, an SGLT2 inhibitor, medicines for alcohol use disorder at his kidney function, and pain relief. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021) **S**
- Losartan 50 mg daily from intake, raised to the maximum tolerated dose, with potassium and creatinine two to four weeks after each start or change, accepting a rise in creatinine of up to 30 percent; less salt. Guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Alcohol: AUDIT, DSM-5-TR criteria and PEth with consent; liver tests and FIB-4; a withdrawal-risk score (PAWSS) and outpatient withdrawal with a five-day chlordiazepoxide taper, daily telephone checks and thiamine; addiction-focused counseling with the clinic's addiction medicine team each week and mutual-help meetings if he wishes; PEth and liver tests at follow-up. Guideline: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025) **S**
- Pain and medicine safety: no naproxen, ibuprofen or other oral anti-inflammatory medicines; acetaminophen up to 2,000 mg a day; no opioids or tramadol with kidney disease and in early recovery, and none at all if naltrexone is started; any new medicine checked for kidney dosing. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension and depression monographs (2026) **S**
- Safety: a structured safety assessment, firearms locked with ammunition apart, small supplies of withdrawal medicine, a written safety plan, the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Work and recovery: keep the morning writing hours from nine to eleven; replace the late-morning drink with a swim or a ride; no alcohol kept in the writing room; PHQ-9 and GAD-7 at intake and follow-up. Guideline: VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Tobacco: advice to stop, with nicotine replacement or varenicline offered when he is ready. Guideline: Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021) **S**
